Načítá se...
Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
Bavituximab is a an unconjugated, chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the phosphatidylserine (PS) expressed on tumor endothelium, with a specific mechanism of action. PS is an anionic membrane phospholipid, physiologically restricted to the internal membrane leafle...
Uloženo v:
| Vydáno v: | Lung Cancer (Auckl) |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5217514/ https://ncbi.nlm.nih.gov/pubmed/28210141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S37981 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|